Correlation Between Histopathological Grading and Appearance of Obstruction With Level of Carsino-Embryonic Antigen (CEA) in Colorectal Carcinoma
AbstractCEA (Carcinoembryonic Antigen) is a blood colorectal tumor marker test that widely used in a clinical setting. The aim of this research is to assess the correlation between carcinoembryonic antigen (CEA) and the degree of tumor differentiation, and between obstruction and age of patients and colorectal adenocarcinoma. This research was a retrospective analytic observational study with a cross-sectional approach. This research used medical record of colorectal carcinoma patients without other malignancy obtained from Wahidin Sudirohusodo Hospital having complete medical records from 2015 to 2017. Initial anamnesis, the result of radiology, laboratory, and the result of pathology were obtained and analyzed using univariate and bivariate analyses with the value of CEA cutoff 5ng/ml. The result of 107 samples, most of the subjects examined is female (60.7%), between the ages of 41-60 years (48.6%) with the levels of CEA >= 5 (55.1%). Histopathology examination results showed most of the differentiate were moderate (68.2%). While the obstruction was found in 34 subjects (31.8%). We found a significant relationship between the presence of an obstruction with levels of CEA (p < 0.001), and degree of differentiating with the CEA levels also showed a significant relationship (p < 0.001). The result of the analysis indicates that there is a significant correlation between CEA level and the degree of differentiation and obstruction. Obstruction has a more significant correlation with high CEA level. There is no significant correlation between age group and CEA level.
Abbaszadegan MR, Tavasoli A, Velayati A, Sima HR, Vosooghinia H, Farzadnia M, et al. Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. World Jurnal of Gastroenterology 2007; 13(10):1528-1533.
Yang H, Xia BQ, Jiang B, Wang G, Yang YP, Chen H, et al. Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: A meta-analysis. Can J Gastroenterol 2013; 27(8):467-475.
Lusikooy RE, Sampetoding S. Characteristics of Colorectal Cancer in Indonesia; The study of the Epidemiology of hospital-based upon Data National Seminar I Makassar Colorectal Cancer (MCC) 2011 on 14 Science Education Center of surgery in Indonesia. Surgical Science Magazine Makassar. 2013;2(2013):7 -11.
Sisik A, Kaya M, Bas G, Basak F, Alimoglu O. CEA, and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients. Asian Pacific Journal of Cancer Prevention. 2013;14:4289-94
Gershon YL.Update of Recommendation for the Use of Tumor markers in Gastrointestinal Cancer. Oncol JC ASCO 2006; 27: 5313
Bajenova O, Tolkunova E, Koshkin S, Malov S, Thomas P, Tomilin A, Obrien S. The role of the carcinoembryonic antigen receptor in colorectal cancer progression. J Integr Oncol 2017; 6:2
Michael JD. Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful. Clinical Chemistry. 2001;47:624-30
Bullard M, Rothenberger DA. Colon, Rectum, and Anus. Schwartz’s Principles of Surgery. McGraw-Hill Medical Publishing Division. 2004; 8: 1055-1118.
Hafiz MA, Yasir MA, Faisal AG. Carcinogenic Embryonic Antigen Levels in Colorectal Carcinoma and its Correlation with Stage of Disease. Ann. Pak. Inst. Med. Sci. 2011; 7(4): 204-207
Wei C, Liu Q, Tan S, Jiang Y. Association between carcinoembryonic antigen, carbohydrate antigen 19-9 and body mass index in colorectal cancer patients. Molecular and Clinical Oncology. 2013;1:879-86
Polat E, Duman U, Duman M, Atici AE, Reyhan E, Dalgic T. Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9in colorectal cancer. Current Oncology. 2014; 21:1-7
Rizaldi A. Pattern Levels Of CEA (Carcinoembryonic Antigen) Pre Operative In Patients With colorectal carcinoma At USU medical Hospital years 2006-2008. 2008.
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clinical chemistry 2001; 47:4
Saito G, Sadahiro S, Okada A, Tanaka A, Suzuki T, Kamijo A, Relation between Carcinoembryonic Antigen Levels in Colon Cancer Tissue and Serum Carcinoembryonic Antigen Levels at Initial Surgery and Recurrence. Oncology 2016;91:85–89
Wang JY. Prognostic Significant of Pre and Postoperative Serum Carcinoembryonic Antigen Levels in Patient with Colorectal Cancer. European Surgical Research. 2007
Labeda I, Uwuratuw JA, Nelwan B, Prihantono P. The Relationship of Cyclooxygenase -2 (COX-2) Expression with Clinical Presentation, Staging, and Degree of Differentiation in Colorectal Cancer. International Journal of Sciences: Basic and Applied Research2017; 35:64-75
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.